Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...
Business Insider22d
First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease
“We believe that therapeutic modalities like gene therapy can change the treatment landscape for people living with the debilitating effects of Parkinson’s disease and look forward to seeing ...
Yahoo Finance23d
First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease
AskBio Inc. (AskBio), a gene therapy company wholly owned and ... in its Phase II clinical trial in patients with Parkinson’s disease (PD). “The randomization of the first participants in ...
Medscape4d
Gene Therapy for Parkinson's Disease
Gene therapy using neurotrophic factors is the most promising disease-modifying approach for Parkinson's disease. The strong safety profile and rapidly increasing experience with adeno-associated ...
Pharmabiz21d
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first participants have been randomized in its phase II clinical ...
pharmaphorum1d
Bayer's two-pronged cell/gene therapy assault on Parkinson's enters clinic
"The potential of BlueRock and AskBio's clinical candidates to treat Parkinsons disease could be immense," said Wolfram Carius, head of cell and gene therapy at Bayer. "For the first time ...
cirm.ca.gov5d
CIRM Awards Nearly $100 Million to Boost Discovery, Translational, and Clinical Disease Research
South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...
pharmaphorum4d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...
The Nation Newspaper4d
Amanda U. Ibe-Enwo: pioneer in gene therapy research
Amanda Ibe-Enwo is a distinguished researcher at Voyager Therapeutics, a biotechnology company based in Massachusetts, USA.
PMLiVE8d
The silent treatment – researching gene silencing for Alzheimer’s, Parkinson’s and motor neurone disease
In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...
GEN2d
Optimizing AAV Gene Delivery: Hitting the Target Safely and Effectively
Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease ...